Multiple Pulmonary Nodules

VIENNA, March 1, 2024 /PRNewswire/ -- At the European Congress of Radiology (ECR) 2024 in Vienna, United Imaging Intelligence (UII), a subsidiary of United Imaging Group, proudly presented its latest advances in medical AI technology. Renowned for its AI-driven healthcare applications, UII's presentation at ECR 2024 marked a significant leap toward "Next Generation Radiology," showcasing intelligent healthcare solutions in alignment with the congress's forward-looking theme. Pioneering AI applications of Large Medical Image Model and Surgical Planning Continue Reading 1 2 Amidst the rapid transformation of the medical technology landscape driven by foundation models, UII adopts these crucial frameworks to enhance 'Next Generation Radiology'. A vital aspect of this advancement is medical imaging AI research. At ECR 2024, UII introduced uAI SAT, an innovative AI-driven annotation tool hosted on its biomedical research platform. Utilizing a large medical image model, uAI SAT enhances intelligent interactive segmentation, significantly shortening annotation times from hours to merely minutes, and contributing to the advancement of scientific research. The uAI Pioneer Portal, UII's prominent exhibit, captivated visitors with its advanced 3D preoperative planning applications tailored for thoracic, hepatobiliary, and urological surgeries. The portal's standout feature is its one-click functionality for diagnostic-level 3D reconstruction of lesions and organs. Coupled with a gesture-controlled 3D monitor, this technology enables users to engage with virtual reality and manipulate detailed models via hand gestures, eliminating the need for 3D goggles or helmets. It offers clinicians an immersive and intuitive visualization of a patient's preoperative plan and intraoperative anatomy. Advancing Full-Stack, Full-Spectrum Innovations for Clinical Diagnosis UII's exhibition extended beyond showcasing technological innovations. It also featured a collection of clinical solutions for neurology, cardiology, chest, and oncology. Among the many breakthroughs, the CE mark certification obtained for specific AI applications within UII's thoracic solutions, including uAI Discovery Pulmonary Nodules, uAI Discover Pneumonia, and uAI Discover Fracture, underscored UII's commitment to healthcare innovation. Utilizing a single chest CT scan, the thoracic solution delivers an assessment of over ten prevalent thoracic conditions, effectively minimizing radiation exposure and the patient's waiting time. In neurology, UII's AI solutions cover the entire continuum of stroke management, from acute care to research. Recognizing the critical nature of timely intervention in stroke management, UII has developed CT-based AI models that enable rapid and accurate identification of strokes, thereby streamlining the treatment workflow. Significant progress has also been made in developing MRI-based diagnostic models for brain diseases, which improve management strategies and contribute to advances in neuroscience research. According to WHO, cardiovascular disease is a leading cause of death worldwide, taking an estimated 17.9 million lives each year. UII's comprehensive cardiac imaging solutions have become indispensable. By integrating assessments from both CT and MRI, UII's cardiovascular solutions provide detailed analyses of anatomical, functional, and tissue characteristics, optimizing image post-processing and significantly reducing the time required for diagnosis. Finally, UII's dedication to oncology is also demonstrated through its comprehensive suite of applications encompassing imaging, screening, diagnostic, and treatment for a variety of cancers, including lung cancer, prostate cancer, breast cancer, and metastatic diseases. UII firmly believes that medical AI represents a pivotal catalyst propelling radiology into a new era of transformation. Having deployed its innovative products in over 3,000 medical institutions worldwide and formed research and product collaborations in Europe, UII remains steadfast in its mission to further expand development and partnerships across the region, striving to make the benefits of medical AI universally accessible. (Notes: Products and features mentioned herein may not be commercially available in all countries. Their future availability cannot be guaranteed.) Photo - Photo -

BOULDER, Colo.--(BUSINESS WIRE)-- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, announced today that it will release financial results for the fourth quarter and year ended December 31, 2023 before the open of trading on Friday, March 1. Biodesix’s management will host a conference call and webcast to discuss its financial results and provide a general business update at 8:30 a.m. Eastern Time on the same day. Listeners can register for the webcast via this link. Analysts who wish to participate in the question and answer session should use this link. A replay of the webcast will be available via the company’s investor website approximately two hours after the call’s conclusion. Participants are advised to join 15 minutes prior to the start time. About Biodesix Biodesix is a leading diagnostic solutions company with a focus in lung disease. The company develops diagnostic tests addressing important clinical questions by combining multi-omics through the power of artificial intelligence. Biodesix offers five Medicare-covered tests for patients with lung diseases. The blood based Nodify Lung® nodule risk assessment testing strategy, consisting of the Nodify XL2® and the Nodify CDT® tests, evaluates the risk of malignancy in pulmonary nodules, enabling physicians to better triage patients to the most appropriate course of action. The blood based IQLung™ strategy for lung cancer patients integrates the GeneStrat® targeted ddPCR™ test, the GeneStrat NGS® test and the VeriStrat® test to support treatment decisions across all stages of lung cancer with results in an average of two to three business days, expediting the time to treatment. Biodesix also leverages the proprietary and advanced Diagnostic Cortex® AI (Artificial Intelligence) platform, to collaborate with many of the world’s leading biotechnology and pharmaceutical companies to solve complex diagnostic challenges in lung disease. For more information about Biodesix, visit biodesix.com. Note Regarding Forward-Looking Statements This press release may contain forward-looking statements that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements contained in this press release other than statements of historical fact, are forward-looking statements. The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “plan,” “expect,” “predict,” “potential,” “opportunity,” “goals,” or “should,” and similar expressions are intended to identify forward-looking statements. Such statements are based on management’s current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors. Biodesix has based these forward-looking statements largely on its current expectations and projections about future events and trends. These forward-looking statements are subject to a number of risks, uncertainties, and assumptions. Forward-looking statements may include information concerning the impact of the COVID-19 pandemic on Biodesix and its operations, its possible or assumed future results of operations, including descriptions of its revenues, profitability, outlook, and overall business strategy. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. The Company's ability to continue as a going concern could cause actual results to differ materially from those contemplated in this press release and additionally, other factors that could cause actual results to differ materially from those contemplated in this press release can be found in the Risk Factors section of Biodesix’s most recent annual report on Form 10-K, filed March 6, 2023 or subsequent quarterly reports on Form 10-Q during 2023, if applicable. Biodesix undertakes no obligation to revise or publicly release the results of any revision to such forward-looking statements, except as required by law. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement. View source version on businesswire.com: Contacts Media: Robbie Lunt robbie.lunt@biodesix.com 1-(866)-432-5930 Investors: Chris Brinzey chris.brinzey@westwicke.com (339) 970-2843 Source: Biodesix, Inc. View this news release online at:

SAN ANTONIO--( BUSINESS WIRE )-- bioAffinity Technologies , Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage cancer and lung disease, today announced that India’s Office of the Controller General of Patents, Designs and Trade Marks has issued a Certificate of Grant of Patent to bioAffinity subsidiary OncoSelect Therapeutics, LLC for its compositions and methods to treat cancer using chemotherapeutic agents conjugated to porphyrins, resulting in targeted delivery of the drugs. The Indian patent, titled “Porphyrin Compounds and Compositions Useful for Treating Cancer” is an important addition to bioAffinity Technologies’ patent portfolio, which includes 16 awarded U.S. and foreign patents and 23 pending patent applications related to its porphyrin-based diagnostic platform and cancer treatment therapeutics. “India’s patent is an acknowledgement of the value of our ongoing research, development and commercialization of porphyrin-based diagnostics and targeted treatments for lung cancer and other diseases,” bioAffinity Technologies’ President and CEO Maria Zannes said. “We are committed to improving the outcome for cancer patients around the world, beginning with lung cancer, the deadliest cancer killer. Strong intellectual property protection for our innovative science benefits not only patients in need of treatment and their physicians, but also our research team and our shareholders as well.” bioAffinity Technologies’ first product, CyPath® Lung, is a porphyrin-based diagnostic test for early-stage lung cancer. Physicians use CyPath® Lung for patients at high risk for developing lung cancer, often after recommended screening reveals indeterminate pulmonary lung nodules that may or may not be malignant. CyPath® Lung is a noninvasive test that uses advanced flow cytometry and artificial intelligence to differentiate patients with cancer from those who do not have the disease. About bioAffinity Technologies, Inc. bioAffinity Technologies, Inc. addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and broad-spectrum cancer treatments. The Company’s first product, CyPath ® Lung , is a noninvasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath ® Lung is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services , a subsidiary of bioAffinity Technologies. Research and optimization of the Company’s platform technologies are conducted in its laboratories at Precision Pathology and The University of Texas at San Antonio. For more information, visit www.bioaffinitytech.com and follow us on LinkedIn , Facebook and X . Forward-Looking Statements Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. These forward-looking statements are based upon current estimates and assumptions and include statements regarding improving the outcome for cancer patients around the world beginning with lung cancer and strong intellectual property protection benefitting patients, their physicians, the Company’s research team and the Company’s shareholders. These forward-looking statements are subject to various risks and uncertainties, many of which are difficult to predict that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the Company’s ability to continue to develop and commercialize porphyrin-based diagnostics and targeted treatments for lung cancer and other diseases and the other factors discussed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, and its subsequent filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. While the Company believes these forward-looking statements are reasonable, readers of this press release are cautioned not to place undue reliance on any forward-looking statements. The information in this release is provided only as of the date of this release, and the Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.